Biotech Decliners: Recro Pharma Inc (NASDAQ:REPH), Ignyta Inc (NASDAQ:RXDX), Alder Biopharmaceuticals Inc (NASDAQ:ALDR), Corcept Therapeutics Incorporated (NASDAQ:CORT)

Aegis started coverage on shares of Recro Pharma Inc. (NASDAQ:REPH) in a research note issued on Thursday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $40.00 price target on the stock. Aegis’ price objective suggests a potential upside of 412.16% from the company’s current price. Recro Pharma Inc (NASDAQ:REPH) stock performance was -7.30%…

Read More

Biotech Bullish Stocks: Applied Genetic Technologies (NASDAQ:AGTC), Alder Biopharmaceuticals (NASDAQ:ALDR), Concert Pharmaceuticals (NASDAQ:CNCE), Recro Pharma Inc (NASDAQ:REPH), Relypsa (NASDAQ:RLYP)

BMO Capital Markets boosted their price target on shares of Applied Genetic Technologies Corp (NASDAQ:AGTC) from $21.00 to $34.00 in a research note issued on Monday. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ target price points to a potential upside of 34.44% from the stock’s previous close. Applied Genetic…

Read More

Healthcare Decliners: SunLink Health Systems, Inc. (NYSEMKT:SSY), Recro Pharma Inc (NASDAQ:REPH), OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), Retrophin Inc (NASDAQ:RTRX)

SunLink Health Systems Inc. (NYSEMKT:SSY) said that net loss for the third-quarter ended March 31, 2014 widened to $964,000 or $0.10 per share, from $186,000 or $0.02 per share last year. Loss from continuing operations for the quarter was $911,000 or $0.10 per share, compared to a loss from continuing operations of $197,000 or $0.02…

Read More

Biotech Bullish Stocks: Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), Reliv International, Inc (NASDAQ:RELV), Recro Pharma Inc (NASDAQ:REPH), Ignyta Inc (NASDAQ:RXDX)

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) has seen a massive down tick in the past few trading sessions, and analysts believe that this downward trajectory might continue for the stock and may lead it to lower levels. Short term traders can short the stock at current levels with a tight stop loss at $11 for targets of…

Read More